In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal-Making Trends

Set Alert for Deal-Making Trends

How Debiopharm’s Licensing Model Bridges The Biotech And Pharma Gap

Sandra von Meier, head of business development and licensing at Debiopharm explains how the company’s distinctive licensing business model is helping bring new drugs to market.

BioPharmaceutical Cancer

Deals Shaping The Industry, May 2024

An interactive look at pharma, medtech and diagnostics deals made during May 2024. Data courtesy of Biomedtracker.

Deals Financing

BIO Roundup: Deal-Making Tips And Tricks

Key insights from the recent the BIO International Convention in San Diego, US.

Deals C-Suite Speaks

AI-Driven CHARM’s Number One Goal: Transitioning To A Clinical-Stage Biotech

Laksh Aithani, CEO of CHARM Therapeutics, discusses key challenges for the flourishing AI drug development sector including finding the right people and the need for more success stories.

Rising Leaders Clinical Trials

Development Versus Dealmaking: How To Obtain A Blockbuster

Most of the companies with blockbuster drugs approved over the past decade oversaw their clinical development internally. Lilly holds the lead with eight blockbusters developed in-house.

Business Strategies Companies

Isomorphic Boasts Its Latest AI Tool

AlphaFold 3 is promising, but for now it stays in the hands of Isomorphic Labs and its partners.

Artificial Intelligence Innovation

Deals in Depth: April 2024

Seven $1bn+ alliances were penned in April. In the top alliance by deal value, Medincell entered a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications. Medincell will receive a $35m upfront payment and is eligible to receive up to $1.9bn in development and commercial milestones, plus mid-single to low-double-digit royalties on net sales.

Deals Financing

Will Actinium Be Big Pharma’s Next Radiopharmaceuticals Acquisition?

With big pharma on a radiopharmaceuticals buying spree, New York-based Actinium Pharmaceuticals has been pointed to as the next potential takeout target.

Market Intelligence Commercial

Deals Shaping The Industry, April 2024

An interactive look at pharma, medtech and diagnostics deals made during April 2024. Data courtesy of Biomedtracker.

Deals Financing

Vividion’s Breakthrough Science Is Fueling Bayer’s Pipeline

Leveraging the biotech entrepreneurial spirit and global pharma resources is a win-win situation in the race to bring meaningful medicines to patients.

Rising Leaders Oncology

Dealmaking Quarterly Statistics, Q1 2024

During Q1, biopharma merger and acquisition deal value reached $37bn, while the potential deal value from alliances was $38.5bn. Device company M&A values reached $3.6bn, while in vitro diagnostics and research tools players’ M&A activity totaled $1bn.

Deals Market Intelligence

BioBytes: AI-Related Deals In Q1 2024

BioBytes presents an overview of AI-related deals in Q1 2024. This is the first in a recurring series of quarterly deal updates.   

Artificial Intelligence Deals
See All
UsernamePublicRestriction

Register